ATX-LPA receptor axis in inflammation and cancer

Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) mediates a plethora of physiological and pathological activities via interactions with a series of high affinity G protein-coupled receptors (GPCR). Both LPA receptor family members and autotaxin (ATX/LysoPLD), the primary LPA-producing enzyme, are aberrantly expressed in many human breast cancers and several other cancer lineages. Using transgenic mice expressing either an LPA receptor or ATX, we recently demonstrated that the ATX-LPA receptor axis plays a causal role in breast tumorigenesis and cancerrelated inflammation, further validating the ATX-LPA receptor axis as a rich therapeutic target in cancer.

[1]  Seigo Nakamura,et al.  Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.

[2]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[3]  Yiling Lu,et al.  Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. , 2009, Cancer cell.

[4]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[5]  Yiling Lu,et al.  Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis , 2009, PloS one.

[6]  J. Chun,et al.  The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. , 2009, Gastroenterology.

[7]  Takao Shimizu,et al.  Identification and Characterization of a Novel Lysophosphatidic Acid Receptor, p2y5/LPA6* , 2009, The Journal of Biological Chemistry.

[8]  Yutong Zhao,et al.  Role of acylglycerol kinase in LPA-induced IL-8 secretion and transactivation of epidermal growth factor-receptor in human bronchial epithelial cells. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[9]  Mingoo Kim,et al.  Analysis of lysophosphatidic acid (LPA) receptor and LPA-induced endometrial prostaglandin-endoperoxide synthase 2 expression in the porcine uterus. , 2008, Endocrinology.

[10]  Yiling Lu,et al.  Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. , 2008, Journal of the National Cancer Institute.

[11]  M. Kurokawa,et al.  Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma , 2008, British journal of haematology.

[12]  D. Braddock,et al.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion , 2008, Molecular Cancer Therapeutics.

[13]  J. Aoki,et al.  Two pathways for lysophosphatidic acid production. , 2008, Biochimica et biophysica acta.

[14]  G. Mills,et al.  Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. , 2008, Biochimica et biophysica acta.

[15]  A. Morris,et al.  Therapeutic potential of autotaxin/lysophospholipase d inhibitors. , 2008, Current drug targets.

[16]  Akira Shiraishi,et al.  Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. , 2008, Biochemical and biophysical research communications.

[17]  M. Ferrer,et al.  A 1,536-well [(35)S]GTPgammaS scintillation proximity binding assay for ultra-high-throughput screening of an orphan galphai-coupled GPCR. , 2008, Assay and drug development technologies.

[18]  Yutong Zhao,et al.  Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) release via C/EBPbeta in human bronchial epithelial cells. , 2008, The Biochemical journal.

[19]  R. Khokha,et al.  Inflammation and breast cancer. Metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer , 2008, Breast Cancer Research.

[20]  T. Macdonald,et al.  α- and β-Substituted phosphonate analogs of LPA as autotaxin inhibitors , 2008 .

[21]  R. García-Becerra,et al.  Regulation of LPA receptor function by estrogens. , 2008, Biochimica et biophysica acta.

[22]  S. Steinberg,et al.  Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. , 2007, Cancer research.

[23]  A. Shiraishi,et al.  The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. , 2007, Biochemical and biophysical research communications.

[24]  G. Mills,et al.  Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression , 2007, Expert Reviews in Molecular Medicine.

[25]  O. Cummings,et al.  Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. , 2007, Cancer research.

[26]  A. J. Valente,et al.  Interleukin-17 Stimulates C-reactive Protein Expression in Hepatocytes and Smooth Muscle Cells via p38 MAPK and ERK1/2-dependent NF-κB and C/EBPβ Activation* , 2007, Journal of Biological Chemistry.

[27]  G. Mills,et al.  Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. , 2007, International journal of oncology.

[28]  Feng Hao,et al.  Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. , 2007, Biochimica et biophysica acta.

[29]  S. Harrison,et al.  An Atomic Model of the Interferon-β Enhanceosome , 2007, Cell.

[30]  G. Prestwich,et al.  α‐Substituted Phosphonate Analogues of Lysophosphatidic Acid (LPA) Selectively Inhibit Production and Action of LPA , 2007, ChemMedChem.

[31]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[32]  T. Macdonald,et al.  Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[33]  W. Maixner,et al.  β2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-κB-independent mechanisms , 2007 .

[34]  R. Sabbadini,et al.  Targeting sphingosine-1-phosphate for cancer therapy , 2006, British Journal of Cancer.

[35]  Y. Kishi,et al.  Autotaxin Stabilizes Blood Vessels and Is Required for Embryonic Vasculature by Producing Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.

[36]  A. Dubin,et al.  GPR92 as a New G12/13- and Gq-coupled Lysophosphatidic Acid Receptor That Increases cAMP, LPA5* , 2006, Journal of Biological Chemistry.

[37]  G. Prestwich,et al.  Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. , 2006, Journal of medicinal chemistry.

[38]  Yutong Zhao,et al.  Regulation of Lysophosphatidic Acid-induced Epidermal Growth Factor Receptor Transactivation and Interleukin-8 Secretion in Human Bronchial Epithelial Cells by Protein Kinase Cδ, Lyn Kinase, and Matrix Metalloproteinases* , 2006, Journal of Biological Chemistry.

[39]  C. Mummery,et al.  Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development , 2006, Molecular and Cellular Biology.

[40]  Y. Kishi,et al.  Autotaxin Is Overexpressed in Glioblastoma Multiforme and Contributes to Cell Motility of Glioblastoma by Converting Lysophosphatidylcholine TO Lysophosphatidic Acid* , 2006, Journal of Biological Chemistry.

[41]  P. Clézardin,et al.  The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Georas,et al.  Lysophosphatidic acid stimulates inflammatory cascade in airway epithelial cells. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[43]  A. Ullrich,et al.  FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. , 2006, Cellular signalling.

[44]  H. Nagawa,et al.  Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. , 2006, The Journal of surgical research.

[45]  Li Feng,et al.  Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. , 2006, Cancer research.

[46]  G. Mills,et al.  Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer , 2006 .

[47]  J. Laitinen,et al.  The basic secretagogue compound 48/80 activates G proteins indirectly via stimulation of phospholipase D–lysophosphatidic acid receptor axis and 5‐HT1A receptors in rat brain sections , 2006, British journal of pharmacology.

[48]  Yiling Lu,et al.  Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. , 2006, Cancer cell.

[49]  G. Mills,et al.  Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and Metastasis* , 2006, Journal of Biological Chemistry.

[50]  Yanhui Hu,et al.  Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. , 2006, Journal of proteome research.

[51]  R. Shridhar,et al.  The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. , 2006, Biochemical and biophysical research communications.

[52]  S. Georas,et al.  Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. , 2006, The Biochemical journal.

[53]  Duane D. Miller,et al.  Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. , 2006, Bioorganic & medicinal chemistry letters.

[54]  H. Nagawa,et al.  Differential expression of lysophosphatidic acid receptor‐2 in intestinal and diffuse type gastric cancer , 2006, Journal of surgical oncology.

[55]  B. H. Shah,et al.  Mechanisms of extracellularly regulated kinases 1/2 activation in adrenal glomerulosa cells by lysophosphatidic acid and epidermal growth factor. , 2005, Molecular endocrinology.

[56]  H. Kanzaki,et al.  Expression of the endothelial cell differentiation gene 7 (EDG‐7), a lysophosphatidic acid receptor, in ovarian tumor , 2005, The journal of obstetrics and gynaecology research.

[57]  Duane D. Miller,et al.  Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. , 2005, Journal of medicinal chemistry.

[58]  Hiroshi Suzuki,et al.  LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing , 2005, Nature.

[59]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[60]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[61]  L. Liotta,et al.  L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin , 2005, Lipids in Health and Disease.

[62]  Hyunsuk Shim,et al.  LPA2 receptor mediates mitogenic signals in human colon cancer cells. , 2005, American journal of physiology. Cell physiology.

[63]  T. Petro.  ERK-MAP-kinases differentially regulate expression of IL-23 p19 compared with p40 and IFN-beta in Theiler's virus-infected RAW264.7 cells. , 2005, Immunology letters.

[64]  F. Marincola,et al.  Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  Y. Kishi,et al.  Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer , 2004, Laboratory Investigation.

[66]  J. Garcia,et al.  Protein Kinase Cδ Mediates Lysophosphatidic Acid-induced NF-κB Activation and Interleukin-8 Secretion in Human Bronchial Epithelial Cells* , 2004, Journal of Biological Chemistry.

[67]  H. Nagawa,et al.  Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma , 2004, Breast Cancer Research.

[68]  G. Mills,et al.  Lysophosphatidic acid production and action: Validated targets in cancer? , 2004, Journal of cellular biochemistry.

[69]  P. Neiman,et al.  Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun , 2004, Oncogene.

[70]  Hyun Cheol Chung,et al.  Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells , 2002, Clinical & Experimental Metastasis.

[71]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[72]  Dylan T Burnette,et al.  Rho-Dependent Contractile Responses in the Neuronal Growth Cone Are Independent of Classical Peripheral Retrograde Actin Flow , 2003, Neuron.

[73]  Nicola Gebbia,et al.  STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.

[74]  S. Georas,et al.  Involvement of Phospholipase D2 in Lysophosphatidate-induced Transactivation of Platelet-derived Growth Factor Receptor-β in Human Bronchial Epithelial Cells* , 2003, Journal of Biological Chemistry.

[75]  D. Im,et al.  Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. , 2003, Molecular pharmacology.

[76]  David I. Smith,et al.  Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  Yan Xu,et al.  A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[78]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[79]  Takao Shimizu,et al.  Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family* , 2003, Journal of Biological Chemistry.

[80]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[81]  P. Kubes,et al.  P38 MAPK: critical molecule in thrombin-induced NF-κB-dependent leukocyte recruitment , 2003 .

[82]  B. Giepmans,et al.  Rac Activation by Lysophosphatidic Acid LPA1Receptors through the Guanine Nucleotide Exchange Factor Tiam1* , 2003, The Journal of Biological Chemistry.

[83]  J. C. Hinshaw,et al.  Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Chun,et al.  Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2 , 2002, Molecular and Cellular Biology.

[85]  D. Feinstein,et al.  p38 MAPK-mediated Transcriptional Activation of Inducible Nitric-oxide Synthase in Glial Cells , 2002, The Journal of Biological Chemistry.

[86]  G. Mills,et al.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production , 2002, The Journal of cell biology.

[87]  Gordon B Mills,et al.  Lysophosphatidic acid is a bioactive mediator in ovarian cancer. , 2002, Biochimica et biophysica acta.

[88]  W. Santos,et al.  Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. , 2001, Molecular pharmacology.

[89]  D. Baker,et al.  Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. , 2001, Molecular pharmacology.

[90]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[91]  E. Mekada,et al.  A Dual Signaling Cascade That Regulates the Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor* , 2001, The Journal of Biological Chemistry.

[92]  O. Kranenburg,et al.  Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists , 2001, Oncogene.

[93]  J. Weiner,et al.  Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[94]  G. Mills,et al.  Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. , 2000, The Biochemical journal.

[95]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[96]  G. Mills,et al.  Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer , 2000, Annals of the New York Academy of Sciences.

[97]  Hiroyuki Arai,et al.  Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid* , 1999, The Journal of Biological Chemistry.

[98]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[99]  A. Hall,et al.  Activation of RhoA by lysophosphatidic acid and Galpha12/13 subunits in neuronal cells: induction of neurite retraction. , 1999, Molecular biology of the cell.

[100]  E. Goetzl,et al.  Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphatidic Acid* , 1998, The Journal of Biological Chemistry.

[101]  K. Jalink,et al.  Exogenous phospholipase D generates Iysophosphatidic acid and activates Ras, Rho and Ca2+ signaling pathways , 1998, Current Biology.

[102]  A. Ullrich,et al.  Signal characteristics of G protein‐transactivated EGF receptor , 1997, The EMBO journal.

[103]  G. Mills,et al.  Elevated levels and altered fatty acid composition of plasma lysophosphatidlycholine(lysoPC) in ovarian cancer patients , 1997, International journal of cancer.

[104]  J. Weiner,et al.  Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex , 1996, The Journal of cell biology.

[105]  A. Tokumura,et al.  A family of phospholipid autacoids: occurrence, metabolism and bioactions. , 1995, Progress in lipid research.

[106]  E. Rosen,et al.  Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction , 1994, The Journal of cell biology.

[107]  P. Heinrich,et al.  The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family , 1994, Molecular and cellular biology.

[108]  P. Hordijk,et al.  Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway. , 1994, The Journal of biological chemistry.

[109]  J. Rubin,et al.  Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. , 1993, Biochimica et biophysica acta.

[110]  K. Fujisawa,et al.  ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. , 1993, The Journal of biological chemistry.

[111]  K. Jalink,et al.  Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[112]  R. Medema,et al.  Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[113]  G. Mills,et al.  Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. , 1990, The Journal of clinical investigation.

[114]  Kees Jalink,et al.  Lysophosphatidate-induced cell proliferation: Identification and dissection of signaling pathways mediated by G proteins , 1989, Cell.

[115]  Maguire Mh,et al.  Darmstoff analogs. 3. Actions of choline esters of acetal phosphatidic acids on visceral smooth muscle , 1989 .